Skip to main content

Select Drug Profiles

Alecensa (Alectinib), an Oral Tyrosine Kinase Inhibitor, Approved for Metastatic Non–Small-Cell Lung Cancer with ALK Mutation

Toujeo (Insulin Glargine) U-300 Approved to Improve Glycemic Control in Adults with Type 1 and Type 2 Diabetes

Onivyde (Irinotecan Liposome Injection) a New Treatment Option for Patients with Metastatic Pancreatic Cancer

Lisa A. Raedler, PhD, RPh

Keytruda (Pembrolizumab) First PD-1 Inhibitor Approved for the Treatment of Patients with Metastatic Non–Small-Cell Lung Cancer Expressing PD-L1

Lisa A. Raedler, PhD, RPh

Imlygic (Talimogene Laherparepvec): First Oncolytic Viral Therapy for the Treatment of Patients with Recurrent Melanoma

Lisa A. Raedler, PhD, RPh

Finacia Foam (Azelaic Acid) the Newest Topical Treatment FDA Approved for the Treatment of Inflammatory Lesions of Rosacea

Ibrance (Palbociclib): First CDK4 and CDK6 Inhibitor Approved for Postmenopausal Women with Metastatic Breast Cancer

Lisa A. Raedler, PhD, RPh

Convergence in Healthcare: Providers, Employers, and Health Plans

Byron C. Scott, MD, MBA

Original Research

Patient Characteristics and Prescribing Patterns Associated with Sofosbuvir Treatment for Chronic HCV Infection in a Commercially Insured Population

Brent M. Tambourine, PharmD, BCPS, Arash Sadeghi, PharmD, Jianing Yang, MD, MS, Karen M. Stockl, PharmD, Heidi C. Lew, PharmD, Brian K. Solow, MD, FAAFP, Josephine N. Tran, PharmD, MS

Stakeholder Perspective

Taking Steps to Cure Chronic Hepatitis C Virus Infection

by Atheer A. Kaddis, PharmD

Original Research

Patient Preferences Regarding Rheumatoid Arthritis Therapies: A Conjoint Analysis

Anthony M. Louder, PhD, RPh, Amitabh Singh, PhD, Kim Saverno, PhD, Joseph C. Cappelleri, PhD, Aaron J. Aten, PharmD, BCPS, Andrew S. Koenig, DO, FACR, Margaret K. Pasquale, PhD

Stakeholder Perspective

Challenges in the Assessment of Patient Preferences among RA Therapies

by Matthew Mitchell, PharmD, MBA, FAMCP

Page 113 of 244
Results 1121 - 1130 of 2438